Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2

Xiao Nan Dong, Yun Qi, Jian Ying, Xi Chen, Ying Hua Chen

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Previously, two candidate multi-peptide-vaccines (MPVs) consisted of five overlapping synthetic peptides covering the antigenic domain B/C (aa693-777) on envelope protein E2 were prepared in our lab. And they successfully induced peptide-specific neutralizing antibodies and provided pigs with complete protection from the lethal challenge of virulent classical swine fever virus (CSFV) strain Shimen. In this study, these five peptides were conjugated to bovine serum albumin (BSA), with which five groups of pigs (n = 10) were inoculated, respectively. Among these candidate peptide-vaccines (PVs), PV-BC1 (BC1: aa693-716) exhibited the most potent protective activity, PV-BC3, PV-BC4 and PV-BC5 (BC3: aa723-745; BC4: aa741-760; BC5: aa757-777) had weaker effects, while no effect of PV-BC2 (BC2: aa712-727) had been detected. Moreover, the polyclonal antibodies induced by PV-BC1 and PV-BC4 were capable of neutralizing C-strain virus in vitro. Thus, a principal sequential neutralizing determinant (aa693-716) and a minor sequential neutralizing determinant (aa741-760) were proved to lie in the antigenic domain B/C, which can be recruited into developing more effective "marker vaccine" by epitope-vaccine strategy. Our study also indicates that scanning with a panel of sequential peptide-immunogens is an effective method to locate sequential neutralizing epitopes.

Original languageEnglish (US)
Pages (from-to)426-434
Number of pages9
JournalVaccine
Volume24
Issue number4
DOIs
StatePublished - Jan 23 2006

Fingerprint

Classical swine fever virus
Subunit Vaccines
subunit vaccines
neutralization
Peptides
peptides
epitopes
Epitopes
Marker Vaccines
Swine
vaccines
swine
synthetic peptides
bovine serum albumin
Bovine Serum Albumin
Neutralizing Antibodies
polyclonal antibodies
neutralizing antibodies
Vaccines
Viruses

Keywords

  • Classical swine fever virus (CSFV)
  • Immunodominant
  • Marker vaccine
  • Peptide vaccine
  • Sequential neutralizing epitope

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2. / Dong, Xiao Nan; Qi, Yun; Ying, Jian; Chen, Xi; Chen, Ying Hua.

In: Vaccine, Vol. 24, No. 4, 23.01.2006, p. 426-434.

Research output: Contribution to journalArticle

Dong, Xiao Nan ; Qi, Yun ; Ying, Jian ; Chen, Xi ; Chen, Ying Hua. / Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2. In: Vaccine. 2006 ; Vol. 24, No. 4. pp. 426-434.
@article{e9856c15a1494be580d5f42eb1404406,
title = "Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2",
abstract = "Previously, two candidate multi-peptide-vaccines (MPVs) consisted of five overlapping synthetic peptides covering the antigenic domain B/C (aa693-777) on envelope protein E2 were prepared in our lab. And they successfully induced peptide-specific neutralizing antibodies and provided pigs with complete protection from the lethal challenge of virulent classical swine fever virus (CSFV) strain Shimen. In this study, these five peptides were conjugated to bovine serum albumin (BSA), with which five groups of pigs (n = 10) were inoculated, respectively. Among these candidate peptide-vaccines (PVs), PV-BC1 (BC1: aa693-716) exhibited the most potent protective activity, PV-BC3, PV-BC4 and PV-BC5 (BC3: aa723-745; BC4: aa741-760; BC5: aa757-777) had weaker effects, while no effect of PV-BC2 (BC2: aa712-727) had been detected. Moreover, the polyclonal antibodies induced by PV-BC1 and PV-BC4 were capable of neutralizing C-strain virus in vitro. Thus, a principal sequential neutralizing determinant (aa693-716) and a minor sequential neutralizing determinant (aa741-760) were proved to lie in the antigenic domain B/C, which can be recruited into developing more effective {"}marker vaccine{"} by epitope-vaccine strategy. Our study also indicates that scanning with a panel of sequential peptide-immunogens is an effective method to locate sequential neutralizing epitopes.",
keywords = "Classical swine fever virus (CSFV), Immunodominant, Marker vaccine, Peptide vaccine, Sequential neutralizing epitope",
author = "Dong, {Xiao Nan} and Yun Qi and Jian Ying and Xi Chen and Chen, {Ying Hua}",
year = "2006",
month = "1",
day = "23",
doi = "10.1016/j.vaccine.2005.08.002",
language = "English (US)",
volume = "24",
pages = "426--434",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2

AU - Dong, Xiao Nan

AU - Qi, Yun

AU - Ying, Jian

AU - Chen, Xi

AU - Chen, Ying Hua

PY - 2006/1/23

Y1 - 2006/1/23

N2 - Previously, two candidate multi-peptide-vaccines (MPVs) consisted of five overlapping synthetic peptides covering the antigenic domain B/C (aa693-777) on envelope protein E2 were prepared in our lab. And they successfully induced peptide-specific neutralizing antibodies and provided pigs with complete protection from the lethal challenge of virulent classical swine fever virus (CSFV) strain Shimen. In this study, these five peptides were conjugated to bovine serum albumin (BSA), with which five groups of pigs (n = 10) were inoculated, respectively. Among these candidate peptide-vaccines (PVs), PV-BC1 (BC1: aa693-716) exhibited the most potent protective activity, PV-BC3, PV-BC4 and PV-BC5 (BC3: aa723-745; BC4: aa741-760; BC5: aa757-777) had weaker effects, while no effect of PV-BC2 (BC2: aa712-727) had been detected. Moreover, the polyclonal antibodies induced by PV-BC1 and PV-BC4 were capable of neutralizing C-strain virus in vitro. Thus, a principal sequential neutralizing determinant (aa693-716) and a minor sequential neutralizing determinant (aa741-760) were proved to lie in the antigenic domain B/C, which can be recruited into developing more effective "marker vaccine" by epitope-vaccine strategy. Our study also indicates that scanning with a panel of sequential peptide-immunogens is an effective method to locate sequential neutralizing epitopes.

AB - Previously, two candidate multi-peptide-vaccines (MPVs) consisted of five overlapping synthetic peptides covering the antigenic domain B/C (aa693-777) on envelope protein E2 were prepared in our lab. And they successfully induced peptide-specific neutralizing antibodies and provided pigs with complete protection from the lethal challenge of virulent classical swine fever virus (CSFV) strain Shimen. In this study, these five peptides were conjugated to bovine serum albumin (BSA), with which five groups of pigs (n = 10) were inoculated, respectively. Among these candidate peptide-vaccines (PVs), PV-BC1 (BC1: aa693-716) exhibited the most potent protective activity, PV-BC3, PV-BC4 and PV-BC5 (BC3: aa723-745; BC4: aa741-760; BC5: aa757-777) had weaker effects, while no effect of PV-BC2 (BC2: aa712-727) had been detected. Moreover, the polyclonal antibodies induced by PV-BC1 and PV-BC4 were capable of neutralizing C-strain virus in vitro. Thus, a principal sequential neutralizing determinant (aa693-716) and a minor sequential neutralizing determinant (aa741-760) were proved to lie in the antigenic domain B/C, which can be recruited into developing more effective "marker vaccine" by epitope-vaccine strategy. Our study also indicates that scanning with a panel of sequential peptide-immunogens is an effective method to locate sequential neutralizing epitopes.

KW - Classical swine fever virus (CSFV)

KW - Immunodominant

KW - Marker vaccine

KW - Peptide vaccine

KW - Sequential neutralizing epitope

UR - http://www.scopus.com/inward/record.url?scp=29244472441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244472441&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.08.002

DO - 10.1016/j.vaccine.2005.08.002

M3 - Article

C2 - 16154668

AN - SCOPUS:29244472441

VL - 24

SP - 426

EP - 434

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 4

ER -